Molecular Partners to hold three poster presentations at AACR 2025

Core Insights - Molecular Partners AG is advancing its clinical-stage biotech initiatives, focusing on DARPin therapeutics for oncology, with significant developments in targeted radiotherapy and T cell engagement strategies [1][3]. Group 1: Product Development - The company is preparing to enter first-in-human (FIH) studies in 2025 for MP0712, a Radio-DARPin targeting DLL3 for small cell lung cancer (SCLC) [1]. - A second 212Pb-based Radio-DARPin is in preclinical development, targeting mesothelin (MSLN) in solid tumors [1]. - Additional preclinical data on a CD3 Switch-DARPin T cell engager with CD2 co-stimulation has shown promise in addressing limitations in solid tumor treatments [1][3]. Group 2: Upcoming Presentations - Molecular Partners will present three posters at the American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled for April 25-30 in Chicago, IL [1][2]. - The presentations will cover the development of 212Pb-based Radio-DARPin therapy for MSLN-positive solid tumors and next-generation CD3 Switch-DARPins [2][3]. Group 3: Company Overview - Molecular Partners AG, founded in 2004, is headquartered in Zurich, Switzerland, and Concord, Massachusetts, focusing on innovative DARPin therapeutics to address unmet medical needs [3]. - The company collaborates with leading pharmaceutical firms to enhance its proprietary programs and expand its oncology portfolio [3].